drug · small molecule

LORBRENA

updated 3mo ago

by $PFE PFIZER INC🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 3

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 5 investigational indications.

targets

ALK tyrosine kinase receptorEML4-ALK

all catalysts(0)

nothing on the calendar yet

Trials studying LORBRENA

phase2A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Canceractive not recruitingn=9
phase2A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphomacompletedn=9
phase1PF-07284892 in Participants With Advanced Solid Tumorsterminatedn=53
phase1AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancernot yet recruitingn=102
phase2A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Canceractive not recruitingn=70
—A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLCactive not recruitingn=50
N/AAnalysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Contextrecruitingn=90
EP1Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusionrecruitingn=15

more trials →

News(2)

OncLive Polls Reveal Picks for Top Lung Cancer Abstracts at ASCO 2026
Lung cancer experts rank key abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.
onclive · 3mo ago
Track the Lung Cancer Abstracts That are Gaining Attention at ASCO 2026
Read on to see what data are poised to shape clinical discussions and decision-making in lung cancer at 2026 ASCO Annual Meeting in Chicago, Illinois.
onclive · 3mo ago

brand

LORBRENA

trade names

Lorbrena, Lorviqua

generic

LORLATINIB

MOA

12.1 Mechanism of Action Lorlatinib is a kinase inhibitor with in vitro activity against ALK and ROS1 as well as TYK1, FER, FPS, TRKA, TRKB, TRKC, FAK, FAK2, and ACK. Lorlatinib demonstrated in vitro activity against multiple mutant forms of the ALK enzyme, including some mutations detected in tumors at the time of disease progression on crizotinib and other ALK inhibitors. In mice subcutaneously implanted with tumors harboring EML4 fusions with either ALK variant 1 or ALK mutations, including the G1202R and I1171T mutations detected in tumors at the time of disease progression on ALK inhibitors, administration of lorlatinib resulted in antitumor activity. Lorlatinib also demonstrated anti-tumor activity and prolonged survival in mice implanted intracranially with EML4-ALK-driven tumor cell lines. The overall antitumor activity of lorlatinib in in vivo models was dose-dependent and correlated with inhibition of ALK phosphorylation.

indication

1 INDICATIONS AND USAGE LORBRENA ® is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. LORBRENA is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. ( 1 , 2.1 )

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 32m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · small molecule

save

LORBRENA

updated 3mo ago

by $PFE PFIZER INC🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 3

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 5 investigational indications.

targets

ALK tyrosine kinase receptorEML4-ALK

all catalysts(0)

nothing on the calendar yet

Trials studying LORBRENA

phase2A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Canceractive not recruitingn=9
phase2A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphomacompletedn=9
phase1PF-07284892 in Participants With Advanced Solid Tumorsterminatedn=53
phase1AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancernot yet recruitingn=102
phase2A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Canceractive not recruitingn=70
—A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLCactive not recruitingn=50
N/AAnalysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Contextrecruitingn=90
EP1Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusionrecruitingn=15

more trials →

News(2)

OncLive Polls Reveal Picks for Top Lung Cancer Abstracts at ASCO 2026
Lung cancer experts rank key abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.
onclive · 3mo ago
Track the Lung Cancer Abstracts That are Gaining Attention at ASCO 2026
Read on to see what data are poised to shape clinical discussions and decision-making in lung cancer at 2026 ASCO Annual Meeting in Chicago, Illinois.
onclive · 3mo ago

brand

LORBRENA

trade names

Lorbrena, Lorviqua

generic

LORLATINIB

MOA

indication

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 32m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

LORBRENA

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying LORBRENA

News(2)

Report a data issue

comments(0)

LORBRENA

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying LORBRENA

News(2)

Report a data issue

comments(0)